Who is SKYSONA for?
SKYSONA is the first and only approved gene therapy that slows the progression of neurologic dysfunction in boys with early, active CALD.‡ SKYSONA is for patients who meet these criteria:
Early,
active
CALD
4–17
years of
age
‡Early, active CALD refers to asymptomatic or mildly symptomatic (NFS ≤ 1) boys who have gadolinium enhancement on brain MRI and Loes scores of 0.5-9.
MRI = magnetic resonance imaging.
Learn more about SKYSONA by exploring these resources
SKYSONAPrescribing Information SKYSONA
Medication Guide SKYSONA
Caregiver Brochure
Stay informed.
Sign up for resources.
Stay up to date on the latest information about SKYSONA. We collect this information to help tailor the content that is delivered to you.
All fields are required.